[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550020":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":45,"centralContacts":50,"locations":56,"responsibleParty":67,"collaborators":32,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":32,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":32,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":32,"overallStatus":58,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,16,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Co-administration of AD-227A and AD-227B","EXPERIMENTAL","AD-227A + AD-227B + Placebo of AD-227C",[13,14,15],"Drug: AD-227A","Drug: AD-227B","Drug: Placebo of AD-227C",{"label":17,"type":18,"description":19,"interventionNames":20},"AD-227A","ACTIVE_COMPARATOR","AD-227A + Placebo of AD-227B + Placebo of AD-227C",[13,21,15],"Drug: Placebo of AD-227B",{"label":23,"type":18,"description":24,"interventionNames":25},"Co-administration of AD-227A and AD-227C","AD-227A + Placebo of AD-227B + AD-227C",[13,26,21],"Drug: AD-227C",[28,33,36,39,42],{"type":29,"name":17,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Per Oral, 1 Tablet, Once a day for 8 weeks",[17,9,23],null,{"type":29,"name":34,"description":30,"armGroupLabels":35,"otherNames":32},"AD-227B",[9],{"type":29,"name":37,"description":30,"armGroupLabels":38,"otherNames":32},"AD-227C",[23],{"type":29,"name":40,"description":30,"armGroupLabels":41,"otherNames":32},"Placebo of AD-227B",[17,23],{"type":29,"name":43,"description":30,"armGroupLabels":44,"otherNames":32},"Placebo of AD-227C",[17,9],[46],{"name":47,"affiliation":48,"role":49},"Chong-Jin Kim","Gangnam CHA Medical Center","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":32,"email":55},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",[57],{"facility":48,"status":58,"city":59,"state":32,"zip":32,"country":60,"countryCode":32,"cosmosGeoPoint":61,"geoPoint":66,"contacts":32},"RECRUITING","Seoul","South Korea",{"type":62,"coordinates":63},"Point",[64,65],126.9784,37.566,{"lat":65,"lon":64},{"type":68,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100550020","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-co-administration-of-ad-227a-and-ad-227b-100550020",false,"NCT06441630","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B","A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Essential Hypertension\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patient with Secondary Hypertension\n* Other exclusions applied","ALL","19 Years",{"count":79,"type":80},251,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension",[86],"Essential Hypertension","2025-02-02",{"date":89,"type":90},"2025-02-04","ACTUAL",{"date":92,"type":90},"2024-07-31",{"date":94,"type":80},"2025-09",{"name":5,"class":6},1]